Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma
Business Wire•03/11/2026•07:00 ET
0
Key Highlights
- ➤Medicare coverage expands for serial Signatera testing in early-stage HCC surveillance
- ➤Signatera sensitivity reached 83% versus 42% for AFP in a 125-patient study
- ➤Signatera provided up to 16.5 months’ lead time ahead of imaging
- ➤Signatera specificity reached 100% in the HCC recurrence-detection study
Expert Statements
Maen A. Abdelrahim, Chief of GI Medical Oncology, Houston Methodist Cancer Center
“Conventional surveillance tools can miss early signs of relapse in HCC. Imaging after liver surgery or transplant is often hard to interpret, and AFP misses many recurrences. Signatera gave us a signal months earlier, and in our study, it helped clarify ambiguous scans.”
Adham Jurdi, Senior Medical Director, GI and Innovations, Medical Affairs, Natera
“We’re proud that Medicare coverage has been extended to patients with hepatocellular carcinoma, the most common form of liver cancer. This milestone gives patients and their physicians greater access to an ultrasensitive, personalized tool to monitor for recurrence.”
Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma
Supports serial testing in the surveillance setting for patients with early-stage HCC
Get started
Create a free account to read the full story.